Coagulation Profile In Diabetes Mellitus And Its Association with Microvascular Complications in Uncontrolled and Controlled Diabetes at Edo Specialist Hospital, Benin-City, South-South, Nigeria
DOI:
https://doi.org/10.31964/mltj.v8i2.493Abstract
Diabetes mellitus induces coagulopathies by glycating haemoglobin, prothrombin, fibrinogen, and other proteins involved in the clotting mechanism. Shortened PTTK and PT represent a hypercoagulable state related to an elevated thrombotic risk and a negative cardiovascular effect, both of which can lead to the onset and progression of microvascular and macrovascular problems. The study aims to compare the coagulation profile in diabetes-related microvascular complications in clients with uncontrolled and controlled diabetes at an Edo specialty hospital in Benin City. A hospital-based case-control study was carried out at ESH in Benin City. Two hundred eighty individuals were recruited for the study, including 215 diabetes patients (55 type I diabetes, 160 type II diabetes, and 65 non-diabetics) attending the outpatient department of ESH in Benin City. Blood was drawn for coagulation and biochemical assays. Diabetes patients had significantly lower levels of PT and PTTK compared to non-diabetes controls (p<0.05). Fibrinogen and D-dimer levels were considerably higher (p<0.05). The PTTK level was much lower in type 2 diabetes than in type 1 diabetes, and there was a significant difference in platelet count between type 1 and type 2 diabetes. Female diabetes patients had lower levels of PTTK and PT than male diabetic patients. Furthermore, in diabetes with complications, the levels of PTTK and platelet count were lower (p0.05). It was discovered that insulin treatment decreased platelet count, whereas sulfonylurea increased fibrinogen levels in people with diabetes. Diabetes may increase the risk of clotting, as indicated by shorter PTTK, PT, and higher fibrinogen and D-dimer levels compared to controls. The coagulation profile should be evaluated as a regular screening test in diabetes patients to reduce the incidence and prevalence of vascular burden and to improve quality of life.References
Abdulrahaman, Y., Dallatu, M.K. (2012). Evaluation of prothrombin time and activated partial thromboplastin in patients with diabetes mellitus. Nigerian Journal of Basic and Applied Sciences. 20(1): 60-63.
Acang, N. & Jalil,F.D. (1993). Hypercoagulation in diabetes mellitus. Southeast Asian Journal of Tropical Medicine Public Health. 24 (Suppl 1): 263-266.
Ajjan, R.,& Grant, P.J. (2006). Coagulation and atherothrombotic disease. Atherosclerosis.186: 240–259.
American Diabetes Association. (2018). Glycemic targets: Standards of medical care in Diabetes. Diabetes Care. 41(Suppl 1):S55-S64.
American Diabetes Association. (2018). Glycemic targets: Standards of medical care in Diabetes. Diabetes Care. 41(Suppl 1):S55-S64.
Anfossi, G., Mularoni, E.M., Burzacca, S., Ponziani, M.C., Massucco, P., Mattiello, L., Cavalot, F., Trovati, M. (1998). Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 21: 121– 126.
Arpaci, D., Saglam, F., Ozdemir, D., Ersoy, R., Cakir, B. (2015). Does glycemic regulation affect hypercoagulable states in diabetic patients? International Journal of Diabetes in Developing Countries. 35(3): 512-15.
Asakawa, H., Tokunaga, K., Kawakami, F. (2000). Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. Journal of Diabetes Complications.14: 121–126.
Barazzoni, R., Kiwanuka, E., Zanetti, M., Cristini, M., Vettore, M., Tessari, P. (2003). Insulin acutely increases fibrinogen produc¬tion in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 52: 1851–1856.
Barham, D. & Trinder, P. (1972). An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst. 97(1151): 142-145.
Becker, A., van der Does, F.E., van Hinsbergh, V.W., Heine, R.J., Bouter, L.M. Stehouwer, C.D. (2003). Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pres¬sure, total cholesterol and triglycerides, but not in HDL cho¬lesterol, fibrinogen, Von Willebrand factor and (pro)insulin. Netherland Journal of Medicine. 61: 129–136.
Beckman, J.A., Creager, M.A., Libby, P. (2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. Journal of American Medical Association. 287(19): 2570-81.
Byberg, L. (1998). Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arteriosclerotic Thrombosis Vascular Biology. 18(2): 258-64.
Ceriello. A. (1993). Coagulation activation in diabetes mellitus: The role of hyperglycaemia and therapeutic prospects. Diabetologia. 36: 1119–1125.
Collier, A. (1992). Free radical activity and hemostatic factors in NIDDM patients with and without micoalbuminuria. Diabetes. 41: p. 909-913.
Dhall, D.P. & Nair, C.H. (1994). Effects of gliclazide on fibrin net¬work. Journal of Diabetes Complications. 8: 231–234.
Erem, C. (2005). Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Medical Principle and Practice. 14: 22-30.
Fanghanel, G., Silva, U., Sanchez-Reyes, L., Sisson, D., Sotres, D., Torres, E.M. (1998). Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Revista de Investigacion Clin. 50: 389–394.
Forouhi, N.G., Wareham, N.J. (2014). Epidemiology of diabetes. Medicine (Abingdon). 42(12): 698-702.
Grundy, S.M. (1998). Hypertriglyceridemia, a therogenic dyslipidemia, and the metabolic syndrome. American Journal of Cardiology. 81(4A): 18B-25B.
Imperatore, G. (1998). Plasma fibrinogen: a new factor of the metabolic syndrome. A population based study. Diabetes Care. 21(4): 649-654.
International Diabetes Federation (2017). Diabetes Atlas: Africa(8th edn).
International Diabetes Federation (2021). Diabetes Atlas: Africa(8th edn).
Jabeen, F., Rizvi, H.A., Aziz, F., Wasti, A.Z. (2013). Hyperglycemic induced variations in haematological indices in Type 2 diabetics. International Journal of Advanced Research.1(8): 322-34.
Kaur, N., Bhat, S., Hussain, S., Singh, K. (2019). Bleeding Time (BT),Clotting Time (CT), Platelet Count and Mean Platelet Volume (MPV) in Type 2 diabetes Mellitus-A case control study. International Journal of Medical Science and Current Research.1(3): 141-46.
Kaveeshwar, S.A., Cornwall, J. (2014). The current state of diabetes mellitus in India. Australas Medical Journal. 7(1): 45-48.
Kharroubi, A.T., Darwish, H.M. (2015). Diabetes mellitus: The epidemic of the century. World Journal of Diabetes. 6(6): 850-67.
Luscher, T.F., Creager, M.A., Beckman, J.A., Cosentino, F. (2003). Diabetes and vascular disease: Pathophysiology, clinical consequences and medical therapy: Part II. Circulation. 108(13):1655-61.
Madan, R. (2010). Coagulation profile in diabetes and its association with diabetic microvascular complications. Journal of Association of Physicians India. 58: 481-484.
Mard-Soltani, M., Dayer, M.R., Ataie, G., Moazedi, A.A., Dayer, M.S., Alavi, S.M. (2011). Coagulation factors evaluation in NIDDM patients. American Journal of Biochemistry and Molecular Biology.1(3): 244-54.
McIntosh, A., Hutchinson, A., Home, P.D., Brown, F., Bruce, A., Damerell, A. (2001). Clinical guidelines and evidence review for type 2 diabetes: Blood Glucose Management. 4: 44
Nolan, R.D. & Vinik,A.I. (1996). Pathogenesis of platelet dysfunction in diabetes. In Diabetes Mellitus: A Fundamental and Clinical Text, ed. LeRoith, D., Olefsky, J.M., Taylor, S.I. : Philadelphia, Lippincott-Raven. p. 832-839.
Nwose, E.U., Richards, R.S., Jelinek, H.F., Kerr, P.G. (2007). d-Dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications. Pathology. 39(2): 252-57
Oyakhire, F.O., Emokpae, M.A.,Enehizena, O.O., Egho,E.O. (2021). Effect of Diabetes Mellitus on Excretory Function of the Liver. Medical Laboratory Technology Journal. 7(2):153-163
Sapkota, B., Shrestha, S.K., Poudel, S. (2013). Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus. BioMed Central Research Notes. 6(1):485.
Schneider, D.J. (2009). Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 32(4): 525-27.
Shetty, A., Vijaya, C., Jayalakshmi, V.J., Lekha, M.B. (2014). Comparison of mean platelet volume, platelet count, total leucocyte and neutrophil counts in normoglycemics, impaired fasting glucose and diabetics. International Journal of Scientific Study. 2(2): 24-27.
Tessari, P., Kiwanuka, E., Millioni, R., Vettore, M., Puricelli, L., Zanetti, M. (2006). Albumin and fibrinogen synthesis and insu¬lin effect in type 2 diabetic patients with normoalbuminuria. Diabetes Care. 29: 323–328.
Zhao, Y., Zhang,J., & Wu,J. (2011). Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 6(1): p. e16470.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 fidelis oyakhire, Babatunde Ishola Gabriel Adejumo, Olufunke Victoria Aiyegbusi, Enehizena Osaro Ogie, Eseoghene Valentine Egho, Promise Bassey Ochannah, Enor Sylvia, Usman Itakure Abdulkadir

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.